maklogo
Market Research Report

Global Drug Repositioning Market Insights, Size, and Forecast By End User (Pharmaceutical Companies, Research Institutions, Contract Research Organizations), By Mechanism of Action (Targeted Therapy, Hormonal Therapy, Immunotherapy, Enzyme Inhibition, Antibiotic Action), By Drug Type (Small Molecule Drugs, Biologics, Combination Therapies, Generics), By Application (Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:28003
Published Date:Jan 2026
No. of Pages:219
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Drug Repositioning Market is projected to grow from USD 43.7 Billion in 2025 to USD 91.5 Billion by 2035, reflecting a compound annual growth rate of 9.2% from 2026 through 2035. Drug repositioning, also known as drug repurposing, involves identifying new therapeutic uses for existing drugs that have already been approved for other indications or are in development. This approach leverages existing safety and pharmacokinetic data, significantly reducing the time and cost associated with traditional drug discovery and development. The market is propelled by several key drivers, including the escalating costs and extended timelines of conventional drug development, the growing prevalence of chronic and rare diseases demanding new treatment options, and the increasing adoption of advanced computational tools and artificial intelligence for drug screening and target identification. Moreover, the expiration of patents for blockbuster drugs has spurred pharmaceutical companies to seek novel applications for their existing portfolios. The market is segmented by Application, Mechanism of Action, Drug Type, and End User, with Pharmaceutical Companies emerging as the leading segment. This dominance is attributable to their substantial R&D investments, extensive drug pipelines, and strategic focus on maximizing the value of their intellectual property.

Global Drug Repositioning Market Value (USD Billion) Analysis, 2025-2035

maklogo
9.2%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Important trends shaping the drug repositioning market include the increasing collaboration between pharmaceutical companies, academic institutions, and contract research organizations to accelerate the discovery and development of repurposed drugs. The rise of genomics and proteomics is enabling more precise identification of drug targets and patient stratification, further enhancing the success rate of repositioning efforts. Furthermore, the growing focus on rare diseases, where traditional drug development is often economically unviable, presents a significant opportunity for drug repurposing. However, market growth faces certain restraints, such as the complexity of identifying new indications for existing drugs, the regulatory hurdles associated with obtaining new approvals for repurposed drugs, and the challenges in intellectual property protection for these applications. Despite these challenges, the market offers substantial opportunities, particularly in areas like oncology, neurological disorders, and infectious diseases, where there remains a high unmet medical need.

North America leads the global drug repositioning market, driven by robust R&D infrastructure, significant investment in life sciences, a high concentration of pharmaceutical and biotechnology companies, and favorable regulatory policies supporting drug innovation. The region also benefits from a strong presence of academic research institutions and well-established venture capital funding for drug development. Conversely, Asia Pacific is poised to be the fastest-growing region. This rapid expansion is fueled by increasing healthcare expenditure, a large patient pool, improving healthcare infrastructure, and the growing focus on research and development in countries like China and India. These nations are actively investing in bioinformatics and computational biology, providing a fertile ground for drug repositioning initiatives. Key players in this competitive landscape include Roche, Bayer, Johnson & Johnson, Teva Pharmaceuticals, Pfizer, Celgene, GSK, Novartis, AbbVie, and AstraZeneca. These companies are actively engaged in strategic alliances, acquisitions, and the integration of artificial intelligence and machine learning platforms to bolster their drug repositioning capabilities and expand their therapeutic portfolios.

Quick Stats

  • Market Size (2025):

    USD 43.7 Billion

  • Projected Market Size (2035):

    USD 91.5 Billion

  • Leading Segment:

    Pharmaceutical Companies (68.4% Share)

  • Dominant Region (2025):

    North America (38.7% Share)

  • CAGR (2026-2035):

    9.2%

Global Drug Repositioning Market Emerging Trends and Insights

AI Driven Repositioning Platforms

AI driven repositioning platforms are transforming drug discovery by leveraging artificial intelligence and machine learning to accelerate the identification of new therapeutic uses for existing drugs. These platforms analyze vast datasets including genomics proteomics clinical trial data and real world evidence to uncover hidden connections between drugs diseases and biological pathways. AI algorithms can predict drug target interactions identify molecular mechanisms of action and pinpoint patient subsets most likely to respond to a particular drug. This capability significantly reduces the time and cost associated with traditional drug development pipelines by providing high confidence candidates for further validation. The technology streamlines the complex process of matching drugs to unmet medical needs offering a more efficient and data informed approach to bringing new treatments to patients faster.

Precision Medicine Drug Repurposing

Precision medicine drug repurposing is a significant trend in the global drug repositioning market. It leverages advancements in genomics, proteomics, and bioinformatics to identify existing drugs that can be repurposed for new indications, particularly within specific patient subgroups. This approach utilizes patient molecular profiles and disease biomarkers to match drugs more effectively, moving beyond empirical testing. By stratifying patients based on their unique biological characteristics, researchers can pinpoint drugs likely to be efficacious for a subset of individuals, even if they were ineffective in broader populations. This minimizes risks and development costs associated with novel drug discovery, as repurposed drugs already have established safety profiles. The trend emphasizes data driven decision making and personalized therapeutic strategies, accelerating the delivery of targeted treatments for unmet medical needs. It represents a paradigm shift towards more efficient and patient centric drug development.

Omics Guided Therapeutic Redirection

Omics guided therapeutic redirection signifies a profound shift in drug repositioning. This trend leverages vast datasets generated by genomics, proteomics, metabolomics, and other omics technologies to identify novel applications for existing drugs. Instead of relying on chance or limited biological understanding, researchers analyze intricate molecular profiles of diseases and drug mechanisms.

By integrating multi omics data, scientists can pinpoint specific pathways or targets a drug modulates, revealing therapeutic potential beyond its original indication. This data driven approach accelerates the discovery of new uses for safe, approved medications, significantly reducing development time and costs associated with new drug creation. It enables precise matching of drugs to diseases based on their molecular signatures, facilitating personalized treatment strategies and expanding the therapeutic utility of a vast existing pharmacopeia. This redirection minimizes risks and capitalizes on known drug safety profiles.

What are the Key Drivers Shaping the Global Drug Repositioning Market

Rising R&D Costs and Success Rate Challenges Driving Repurposing Adoption

Pharmaceutical companies face immense pressure from escalating research and development expenditures. Bringing a new drug to market requires billions of dollars and a decade or more of intensive work. Compounding this challenge is the persistently low success rate of traditional de novo drug discovery, with many promising compounds failing in late stage clinical trials. These combined factors create a compelling need for more efficient and cost effective drug development strategies. Repurposing existing drugs offers a solution by leveraging compounds with known safety profiles and pharmacokinetic data. This significantly reduces development time and financial outlay, mitigating the risks associated with entirely novel drug candidates. Therefore, the inherent difficulties and high costs of traditional R&D are powerful drivers for the adoption of drug repurposing across the industry.

Increasing Chronic Disease Prevalence and Unmet Medical Needs Fueling Innovation

The growing burden of chronic diseases globally is a primary driver for drug repositioning. Conditions like diabetes, cardiovascular diseases, cancer, and neurodegenerative disorders affect millions, often requiring long term management and a range of therapeutic options. Despite significant progress, many patients still experience inadequate disease control or suffer from debilitating side effects of existing treatments. This unmet medical need creates a substantial demand for novel and improved therapies. Drug repositioning offers a faster, de risked pathway to address these gaps by identifying new uses for existing, approved drugs. It leverages known safety profiles and manufacturing processes, accelerating the development of treatments for prevalent chronic conditions and improving patient outcomes.

Technological Advancements in AI, Big Data, and Genomics Accelerating Drug Discovery

Technological advancements in artificial intelligence, Big Data, and genomics are rapidly transforming drug discovery, making drug repositioning more efficient and effective. AI algorithms can analyze vast datasets of existing drugs, patient information, and disease profiles to identify promising candidates for new indications. Big Data platforms integrate complex biological, chemical, and clinical data, allowing researchers to uncover hidden relationships and predict drug efficacy. Genomics provides a deeper understanding of disease mechanisms at the molecular level, enabling the identification of novel therapeutic targets for existing drugs. These combined technologies accelerate the identification of new uses for old drugs, reduce research and development costs, and bring treatments to patients faster by leveraging previously known safety profiles and manufacturing processes.

Global Drug Repositioning Market Restraints

Lack of Standardized Regulatory Pathways for Repurposed Drugs

The absence of clear, consistent regulatory guidelines across different countries poses a significant hurdle for drug repositioning. Each region or nation often maintains unique approval processes and data requirements for drugs seeking new indications. This fragmented landscape necessitates extensive, redundant efforts from pharmaceutical companies to navigate varied legal and scientific standards.

Companies must often repeat preclinical and clinical studies or adapt existing data to satisfy diverse regulatory bodies, leading to substantial delays and increased development costs. Such inconsistencies create uncertainty and risk for investors and drug developers, making it challenging to predict timelines and secure approvals globally. This lack of harmonization inhibits the efficient advancement of promising repositioned therapies from research to market, ultimately slowing patient access to potentially life changing treatments.

High Development Costs and Uncertain ROI for Repositioned Therapies

High development costs pose a significant hurdle for repositioned therapies. Bringing a repurposed drug to market still requires substantial investment in preclinical validation, clinical trials across new indications, and regulatory submissions. These costs can rival those of novel drug development, even with existing safety data.

Compounding this is the uncertain return on investment. While repositioned drugs offer advantages like reduced risk and faster development, market uptake and commercial success for new indications are not guaranteed. Payers may be reluctant to reimburse at high prices for older drugs, and physicians may favor established treatments. This creates a financial disincentive for pharmaceutical companies, making them hesitant to commit extensive resources to projects with an unclear path to profitability, ultimately limiting growth in the global drug repositioning market.

Global Drug Repositioning Market Opportunities

Unlocking New Indications for Existing Drugs to Address High Unmet Medical Needs

The significant opportunity lies in efficiently discovering and validating new therapeutic applications for drugs already approved or advanced in development. This strategic approach, known as drug repositioning, harnesses the known safety profiles and pharmacokinetic data of existing compounds. By identifying novel indications, especially for conditions with high unmet medical needs such as rare diseases, specific cancers, or neurodegenerative disorders, the development timeline and costs are dramatically reduced compared to de novo drug discovery. It accelerates the delivery of much needed treatments to patients globally who currently lack effective options. The global drug repositioning market offers immense potential for innovation, with regions like Asia Pacific exhibiting remarkable growth and interest in these expedited pathways. This method presents a compelling, lower risk pathway to address critical health challenges, fostering both improved patient outcomes and substantial commercial value. This innovative paradigm efficiently converts existing pharmaceutical assets into novel life saving solutions.

Leveraging AI-Powered Platforms for Accelerated Drug Repositioning Across Therapeutic Areas

Leveraging AI powered platforms presents a paramount opportunity in the global drug repositioning market. These advanced computational tools revolutionize how existing drugs are identified for new therapeutic applications. By rapidly sifting through immense datasets encompassing molecular profiles, patient data, clinical trial results, and scientific literature, AI algorithms can uncover previously unrecognized links between compounds and diverse diseases. This capability dramatically accelerates the typically lengthy and resource intensive process of drug development. Companies can swiftly pinpoint promising candidates for repositioning across a wide spectrum of therapeutic areas, from oncology to rare diseases, significantly expanding treatment options. This expedited approach not only slashes research and development costs but also drastically shortens time to market for vital medicines. The precision and speed offered by AI driven platforms enhance successful repositioning, driving innovation and addressing critical unmet medical needs more efficiently worldwide. This strategic advantage positions firms to deliver transformative therapies faster and more cost effectively.

Global Drug Repositioning Market Segmentation Analysis

Key Market Segments

By Application

  • •Oncology
  • •Neurology
  • •Cardiology
  • •Infectious Diseases
  • •Metabolic Disorders

By Mechanism of Action

  • •Targeted Therapy
  • •Hormonal Therapy
  • •Immunotherapy
  • •Enzyme Inhibition
  • •Antibiotic Action

By Drug Type

  • •Small Molecule Drugs
  • •Biologics
  • •Combination Therapies
  • •Generics

By End User

  • •Pharmaceutical Companies
  • •Research Institutions
  • •Contract Research Organizations

Segment Share By Application

Share, By Application, 2025 (%)

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Metabolic Disorders
maklogo
$43.7BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why are Pharmaceutical Companies dominating the Global Drug Repositioning Market?

Pharmaceutical Companies lead the drug repositioning market due to their extensive R&D capabilities, significant financial resources, and established pipelines for drug development and commercialization. Their core business revolves around identifying and bringing new therapies to market, and drug repositioning offers a cost effective and time efficient strategy to expand their product portfolios, mitigate development risks, and potentially extend patent life for existing drugs, leveraging vast libraries of previously tested compounds.

Which application area is significantly driving the Global Drug Repositioning Market?

Oncology is a pivotal application area fueling the drug repositioning market. The complexity of cancer, coupled with the urgent need for new and more effective treatments, drives continuous research into existing drugs for novel anti cancer properties. The high unmet medical need, extensive research funding, and the potential to identify synergistic combinations or alternative mechanisms of action within established oncology or non oncology drugs make this segment particularly active for repositioning efforts.

What drug type frequently facilitates advancements in the Global Drug Repositioning Market?

Small Molecule Drugs frequently facilitate advancements in the drug repositioning market. Their well characterized properties, known safety and efficacy profiles from previous clinical trials, and often clear mechanisms of action make them ideal candidates for exploring new therapeutic applications. These molecules can interact with various biological targets, offering versatility and a higher probability of identifying new indications compared to more complex biologics, expediting the development process significantly.

Global Drug Repositioning Market Regulatory and Policy Environment Analysis

Global drug repositioning benefits from an evolving regulatory landscape designed to accelerate new indications for existing drugs. Agencies like the FDA, EMA, and PMDA increasingly offer streamlined pathways leveraging established safety profiles. This often reduces preclinical data requirements, focusing instead on robust clinical evidence for the new therapeutic use. Orphan Drug Designations are significant incentives, providing market exclusivity and tax credits for rare disease applications. Intellectual property considerations are crucial, with new use patents and data exclusivity periods extending market protection for repurposed medicines. However, variations persist across jurisdictions regarding the acceptance of real world evidence and the specifics of clinical trial design for repurposed drugs. Policy frameworks aim to balance patient access with pharmaceutical innovation, recognizing the cost efficiency and reduced development risk associated with repositioning. Harmonization efforts are underway but regional nuances in reimbursement policies and regulatory submission requirements remain influential factors for market access and commercial viability.

Which Emerging Technologies Are Driving New Trends in the Market?

Innovations in the global drug repositioning market are driven by advanced artificial intelligence and machine learning algorithms. These technologies swiftly analyze vast datasets including genomics, proteomics, transcriptomics, and real world evidence, drastically accelerating candidate identification. Bioinformatics platforms integrate diverse omics data, enabling sophisticated target identification and drug protein interaction predictions. Network pharmacology and systems biology approaches provide a holistic understanding of disease pathways, uncovering novel repurposing opportunities.

Emerging technologies further enhance this landscape. Big data analytics combined with high throughput screening and computational chemistry refine drug selection, improving success rates and reducing development costs. Explainable AI is gaining traction for deciphering underlying mechanisms of action, fostering trust and precision. Blockchain technology holds promise for secure and transparent data sharing across research institutions. These advancements are crucial for addressing unmet medical needs, particularly in oncology, neurodegenerative diseases, and infectious diseases, by rapidly expanding therapeutic options with established safety profiles. The focus remains on faster, cost effective drug discovery.

Global Drug Repositioning Market Regional Analysis

Global Drug Repositioning Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
38.7%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 38.7% share

North America stands as the dominant region in the global drug repositioning market, holding a substantial 38.7% market share. This leadership position is primarily driven by several key factors. The region boasts a highly developed pharmaceutical and biotechnology industry, fostering significant investment in research and development initiatives. Furthermore, a robust regulatory framework and well-established healthcare infrastructure support the adoption and commercialization of repositioned drugs. The presence of numerous academic institutions and research organizations also contributes to a strong innovation ecosystem. High healthcare expenditure and a proactive approach towards new therapeutic options further solidify North America's leading role, enabling extensive exploration and utilization of drug repositioning strategies for unmet medical needs.

Fastest Growing Region

Asia Pacific · 12.4% CAGR

Asia Pacific is poised to be the fastest growing region in the global drug repositioning market, exhibiting a remarkable CAGR of 12.4% during the forecast period of 2026 to 2035. This accelerated growth is primarily driven by expanding pharmaceutical research and development activities across the region. Increased healthcare expenditure, coupled with a rising prevalence of chronic diseases, fuels the demand for novel and affordable therapeutic solutions. Furthermore, supportive government initiatives and growing investments in biotechnology and life sciences contribute significantly to the market expansion. The presence of a large patient pool and developing healthcare infrastructure in countries like China and India further solidify Asia Pacific's leading position.

Impact of Geopolitical and Macroeconomic Factors

Geopolitically, the drug repositioning market faces both tailwinds and headwinds. Increasing global emphasis on healthcare cost containment and access to affordable therapeutics, particularly in emerging economies, fosters demand for repositioned drugs due to lower development costs and faster market entry. However, intellectual property rights enforcement across diverse jurisdictions remains a complex challenge. Varying regulatory frameworks and approval processes across major markets like the US, EU, and Asia, coupled with geopolitical tensions impacting supply chains for active pharmaceutical ingredients, create fragmentation and add layers of risk to market expansion.

Macroeconomically, the market benefits from an aging global population and rising prevalence of chronic diseases, driving a continuous need for novel treatment options. Healthcare expenditure growth, fueled by both public and private investment, supports research and development in drug repositioning. Inflationary pressures on R&D costs and manufacturing, however, could impact profitability and investment. Furthermore, shifts in public health priorities and government funding for specific disease areas can significantly influence investment and commercialization strategies for repositioned drugs targeting those conditions.

Recent Developments

  • March 2025

    Johnson & Johnson announced a strategic partnership with a leading AI-driven drug discovery startup. This collaboration aims to leverage artificial intelligence and machine learning to identify novel drug repositioning candidates for neurological disorders, accelerating the screening and validation process.

  • September 2024

    Pfizer launched a new global initiative focused on rare disease drug repositioning, committing significant R&D investment over the next five years. This program will utilize existing drug libraries to explore new therapeutic indications for conditions with high unmet medical needs, particularly in pediatric rare diseases.

  • February 2025

    Novartis completed the acquisition of a specialized bioinformatics company renowned for its proprietary genomics data analysis platform. This acquisition enhances Novartis's capabilities in identifying promising drug repositioning opportunities by integrating advanced genomic insights into their drug development pipeline.

  • July 2024

    AstraZeneca announced a successful Phase II clinical trial for a repositioned oncology drug, showing significant efficacy in a previously unapproved indication for a specific type of solid tumor. This development highlights the potential for existing therapies to address new cancer types with a faster development pathway.

Key Players Analysis

Roche and Pfizer lead with substantial R&D investments, leveraging genomics and AI for novel repositioning candidates. Bayer and J&J actively pursue strategic partnerships and M&A for pipeline expansion. Teva and GSK focus on repurposing established drugs, driven by cost efficiency and faster market entry. Novartis and AbbVie utilize advanced bioinformatics and high throughput screening to identify new indications for existing therapies, fueling market growth.

List of Key Companies:

  1. Roche
  2. Bayer
  3. Johnson & Johnson
  4. Teva Pharmaceuticals
  5. Pfizer
  6. Celgene
  7. GSK
  8. Novartis
  9. AbbVie
  10. AstraZeneca
  11. Eli Lilly
  12. Regeneron Pharmaceuticals
  13. Sanofi
  14. Amgen
  15. Merck
  16. BristolMyers Squibb

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 43.7 Billion
Forecast Value (2035)USD 91.5 Billion
CAGR (2026-2035)9.2%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Application:
    • •Oncology
    • •Neurology
    • •Cardiology
    • •Infectious Diseases
    • •Metabolic Disorders
  • By Mechanism of Action:
    • •Targeted Therapy
    • •Hormonal Therapy
    • •Immunotherapy
    • •Enzyme Inhibition
    • •Antibiotic Action
  • By Drug Type:
    • •Small Molecule Drugs
    • •Biologics
    • •Combination Therapies
    • •Generics
  • By End User:
    • •Pharmaceutical Companies
    • •Research Institutions
    • •Contract Research Organizations
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Drug Repositioning Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.1.1. Oncology
5.1.2. Neurology
5.1.3. Cardiology
5.1.4. Infectious Diseases
5.1.5. Metabolic Disorders
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Mechanism of Action
5.2.1. Targeted Therapy
5.2.2. Hormonal Therapy
5.2.3. Immunotherapy
5.2.4. Enzyme Inhibition
5.2.5. Antibiotic Action
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Drug Type
5.3.1. Small Molecule Drugs
5.3.2. Biologics
5.3.3. Combination Therapies
5.3.4. Generics
5.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
5.4.1. Pharmaceutical Companies
5.4.2. Research Institutions
5.4.3. Contract Research Organizations
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Drug Repositioning Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.1.1. Oncology
6.1.2. Neurology
6.1.3. Cardiology
6.1.4. Infectious Diseases
6.1.5. Metabolic Disorders
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Mechanism of Action
6.2.1. Targeted Therapy
6.2.2. Hormonal Therapy
6.2.3. Immunotherapy
6.2.4. Enzyme Inhibition
6.2.5. Antibiotic Action
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Drug Type
6.3.1. Small Molecule Drugs
6.3.2. Biologics
6.3.3. Combination Therapies
6.3.4. Generics
6.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
6.4.1. Pharmaceutical Companies
6.4.2. Research Institutions
6.4.3. Contract Research Organizations
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Drug Repositioning Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.1.1. Oncology
7.1.2. Neurology
7.1.3. Cardiology
7.1.4. Infectious Diseases
7.1.5. Metabolic Disorders
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Mechanism of Action
7.2.1. Targeted Therapy
7.2.2. Hormonal Therapy
7.2.3. Immunotherapy
7.2.4. Enzyme Inhibition
7.2.5. Antibiotic Action
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Drug Type
7.3.1. Small Molecule Drugs
7.3.2. Biologics
7.3.3. Combination Therapies
7.3.4. Generics
7.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
7.4.1. Pharmaceutical Companies
7.4.2. Research Institutions
7.4.3. Contract Research Organizations
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Drug Repositioning Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.1.1. Oncology
8.1.2. Neurology
8.1.3. Cardiology
8.1.4. Infectious Diseases
8.1.5. Metabolic Disorders
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Mechanism of Action
8.2.1. Targeted Therapy
8.2.2. Hormonal Therapy
8.2.3. Immunotherapy
8.2.4. Enzyme Inhibition
8.2.5. Antibiotic Action
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Drug Type
8.3.1. Small Molecule Drugs
8.3.2. Biologics
8.3.3. Combination Therapies
8.3.4. Generics
8.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
8.4.1. Pharmaceutical Companies
8.4.2. Research Institutions
8.4.3. Contract Research Organizations
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Drug Repositioning Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.1.1. Oncology
9.1.2. Neurology
9.1.3. Cardiology
9.1.4. Infectious Diseases
9.1.5. Metabolic Disorders
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Mechanism of Action
9.2.1. Targeted Therapy
9.2.2. Hormonal Therapy
9.2.3. Immunotherapy
9.2.4. Enzyme Inhibition
9.2.5. Antibiotic Action
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Drug Type
9.3.1. Small Molecule Drugs
9.3.2. Biologics
9.3.3. Combination Therapies
9.3.4. Generics
9.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
9.4.1. Pharmaceutical Companies
9.4.2. Research Institutions
9.4.3. Contract Research Organizations
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Drug Repositioning Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.1.1. Oncology
10.1.2. Neurology
10.1.3. Cardiology
10.1.4. Infectious Diseases
10.1.5. Metabolic Disorders
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Mechanism of Action
10.2.1. Targeted Therapy
10.2.2. Hormonal Therapy
10.2.3. Immunotherapy
10.2.4. Enzyme Inhibition
10.2.5. Antibiotic Action
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Drug Type
10.3.1. Small Molecule Drugs
10.3.2. Biologics
10.3.3. Combination Therapies
10.3.4. Generics
10.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
10.4.1. Pharmaceutical Companies
10.4.2. Research Institutions
10.4.3. Contract Research Organizations
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Roche
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Bayer
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Johnson & Johnson
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Teva Pharmaceuticals
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Pfizer
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Celgene
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. GSK
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Novartis
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. AbbVie
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. AstraZeneca
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Eli Lilly
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Regeneron Pharmaceuticals
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Sanofi
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Amgen
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Merck
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. BristolMyers Squibb
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Drug Repositioning Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 2: Global Drug Repositioning Market Revenue (USD billion) Forecast, by Mechanism of Action, 2020-2035

Table 3: Global Drug Repositioning Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035

Table 4: Global Drug Repositioning Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 5: Global Drug Repositioning Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Drug Repositioning Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 7: North America Drug Repositioning Market Revenue (USD billion) Forecast, by Mechanism of Action, 2020-2035

Table 8: North America Drug Repositioning Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035

Table 9: North America Drug Repositioning Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 10: North America Drug Repositioning Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Drug Repositioning Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 12: Europe Drug Repositioning Market Revenue (USD billion) Forecast, by Mechanism of Action, 2020-2035

Table 13: Europe Drug Repositioning Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035

Table 14: Europe Drug Repositioning Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 15: Europe Drug Repositioning Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Drug Repositioning Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 17: Asia Pacific Drug Repositioning Market Revenue (USD billion) Forecast, by Mechanism of Action, 2020-2035

Table 18: Asia Pacific Drug Repositioning Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035

Table 19: Asia Pacific Drug Repositioning Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 20: Asia Pacific Drug Repositioning Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Drug Repositioning Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 22: Latin America Drug Repositioning Market Revenue (USD billion) Forecast, by Mechanism of Action, 2020-2035

Table 23: Latin America Drug Repositioning Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035

Table 24: Latin America Drug Repositioning Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 25: Latin America Drug Repositioning Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Drug Repositioning Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 27: Middle East & Africa Drug Repositioning Market Revenue (USD billion) Forecast, by Mechanism of Action, 2020-2035

Table 28: Middle East & Africa Drug Repositioning Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035

Table 29: Middle East & Africa Drug Repositioning Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 30: Middle East & Africa Drug Repositioning Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;